Home » Topics » Regulatory » EMA

EMA
RSS

EMA to begin review of Pfizer's tofacitinib MAA for rheumatoid arthritis

Nov. 22, 2011

CHMP recommends extended indication for Rebif in patients with early signs of MS

Nov. 21, 2011

Starpharma reaches agreement with EMA on phase III program for VivaGel

Nov. 21, 2011

AstraZeneca receives positive CHMP opinion for vandetanib

Nov. 21, 2011

EMA accepts Nuedexta MAA for filing

Nov. 18, 2011

AMT's gene therapy for hemophilia B given orphan drug status in Europe

Nov. 16, 2011

FDA and EMA accept Astellas' submissions for mirabegron

Nov. 15, 2011

Merck Sharp & Dohme withdraws MAA for fixed-dose combination of sitagliptin and pioglitazone

Nov. 15, 2011

EC withdraws marketing authorization for Ablavar

Nov. 14, 2011

Novartis presents key developments of third quarter 2011

Nov. 11, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...